💊 Three of the most expensive medicines ever approved in Japan—including the world's first drug derived from iPS cells—are about to be covered by the country's public health insurance. On May 13, 2026, Japan's pricing authority cleared three regenerative medicines for insurance coverage starting May 20, with sticker prices ranging from roughly $352,000 to over $1 million per treatment. Here's what each drug does, why these therapies cost so much, how Japanese patients are protected from the bills, and whether the prices might ever come down.

What was approved, and when

On May 13, 2026, the Central Social Insurance Medical Council (中央社会保険医療協議会, "Chuikyo")—the body that sets prices for everything covered by Japan's public health insurance—approved insurance coverage for three regenerative medicines. All three were officially added to the national drug price list on May 20, 2026, meaning that from that date, eligible patients can receive them through Japan's universal health insurance system.

The three products are:

  • Amshepri (general name: ragnaprocel) — Sumitomo Pharma. An iPS cell-derived treatment for Parkinson's disease.
  • Akugo Intracerebral Injection (general name: vandefitemcel) — SanBio. A bone-marrow-derived stem cell therapy for chronic motor paralysis after traumatic brain injury.
  • Zolgensma Intrathecal (general name: onasemnogene abeparvovec) — Novartis Pharma. A gene therapy for spinal muscular atrophy (SMA) patients aged 2 and older.

A fourth listing on the same day—a low-dose contrast agent called Amberbist—was approved alongside several smaller-volume rare-disease drugs (Sohonos for fibrodysplasia ossificans progressiva, Dojolvi for long-chain fatty acid oxidation disorders, Inrebic for myelofibrosis). But the three regenerative medicines above are what's making headlines, because of their unprecedented prices.

Amshepri: the world's first iPS cell drug

Amshepri targets Parkinson's disease, a progressive neurological disorder in which the brain gradually loses the dopamine-producing neurons that help control movement. Patients experience tremors, stiffness, and slowed movement that worsen over years. Existing oral drugs like levodopa work well at first but lose effectiveness over time, and many patients eventually reach a stage where their daily life is dominated by "off" periods when medication wears off.

Amshepri is a cell therapy. Scientists start with induced pluripotent stem cells (iPS cells)—ordinary adult cells that have been reprogrammed back to an embryonic-like state and can then be coaxed into any cell type. The iPS cells are differentiated into dopamine-producing neural precursor cells, which are then surgically implanted into the patient's brain to replace the neurons lost to the disease.

The product was approved on March 6, 2026 under Japan's "conditional and time-limited approval" pathway, which lets drugs reach patients while additional clinical data is collected. According to Sumitomo Pharma, this is the world's first approved drug derived from iPS cells—a milestone for a technology pioneered by Kyoto University Professor Shinya Yamanaka, who won the 2012 Nobel Prize for the discovery.

The official price is ¥55,306,737 per patient (approximately $352,000) for a set of 18 vials. Sumitomo Pharma projects 133 patients at peak (fiscal year 2035), and annual sales of about ¥7.4 billion ($47 million). According to Nikkei, the first actual treatment in clinical use is expected around autumn 2026.

A note on what Amshepri does not do: it is approved only for patients whose existing drug therapies have stopped providing adequate relief. It is not a cure for Parkinson's disease, and long-term safety and efficacy data are still being collected.

Akugo: stem cells for traumatic brain injury

Akugo Intracerebral Injection is for adults left with chronic motor paralysis after traumatic brain injury (TBI)—the kind of long-lasting limb weakness or impaired movement that persists months or years after a head trauma. According to SanBio, before this drug there was no treatment that could meaningfully improve motor function in chronic-stage TBI patients; rehabilitation was effectively the only option.

The product is made from bone-marrow-derived mesenchymal stem cells from healthy donors, briefly modified to enhance their regenerative properties, then surgically injected into the brain near the site of injury. The cells are thought to release neurotrophic and growth factors that support the brain's own repair mechanisms.

Akugo received conditional and time-limited approval in Japan in July 2024 as the world's first cell therapy approved for traumatic brain injury, but the path to commercialization was rocky. Manufacturing problems—including reduced cell yields and a foreign matter contamination issue—delayed launch for nearly two years.

The approved Phase 2 STEMTRA trial, published in Neurology, showed improvement on the Fugl-Meyer Motor Scale (a standard measure of motor recovery) at six months, with effects sustained through 48 weeks. New safety concerns were not raised in the trial; headache was the most common adverse event.

The price is ¥72,716,528 per dose (approximately $463,000). SanBio projects 39 patients at peak and annual sales of about ¥2.8 billion ($18 million).

Zolgensma Intrathecal: a new route for an existing gene therapy

The third drug, Zolgensma Intrathecal, is the more complicated story. Zolgensma is a one-time gene therapy for spinal muscular atrophy (SMA), a rare and devastating neuromuscular disease caused by mutations in the SMN1 gene. Without functional SMN protein, motor neurons in the spinal cord die, and patients lose the ability to move, swallow, and eventually breathe. SMA is a designated intractable disease in Japan, with 943 certificate-holders recorded in fiscal year 2024.

An intravenous (IV) version of Zolgensma has been available in Japan since 2020, with an official price of ¥167,077,222—until now, the most expensive single drug ever covered by Japanese insurance. But the IV version is only approved for patients under two years old.

The new intrathecal version—delivered directly into the spinal fluid via a lumbar puncture rather than an IV drip—is approved for SMA patients aged 2 and older who test negative for anti-AAV9 antibodies. According to Novartis, it was approved in Japan in April 2026 based on the STEER trial (for treatment-naive patients) and the STRENGTH trial (for patients switching from other SMA therapies), both of which showed motor function improvement or maintenance.

The intrathecal version was approved in the U.S. in November 2025 for the same indication. The Japanese price is identical to the IV version at ¥167,077,222 per patient (approximately $1.06 million). Novartis projects peak annual sales of about ¥4.3 billion ($27 million).

For Japanese SMA patients aged 2 or older who never received Zolgensma as infants—either because they were diagnosed later, or because the IV version wasn't available in time—this is the first gene therapy option in Japan.

Why are these drugs so expensive?

The short answer is that Japan calculates the price of a brand-new drug with no comparable existing product using a method called the cost-calculation method (原価計算方式, genka keisan hōshiki). The formula adds up the manufacturer's reported costs for raw materials, labor, manufacturing, and general administration, then adds projected operating profit, distribution costs, and consumption tax. For genuinely novel drugs, additional "innovation premiums" can apply.

For these three drugs in particular, several factors push the underlying cost very high:

Manufacturing is genuinely complicated. Regenerative medicines are not chemicals that can be mass-produced in a tank. Amshepri requires culturing and differentiating live iPS cells. Akugo requires harvesting bone marrow cells, genetically modifying them temporarily, and expanding them in culture. Zolgensma requires producing modified adeno-associated viruses that carry the SMN1 gene. According to a 2023 industry paper from the Forum for Innovative Regenerative Medicine (FIRM), regenerative medicine production typically requires specialized cold-chain logistics, dedicated supply chains, and high per-batch costs. Some batches fail entirely, and those losses are borne by the manufacturer.

R&D recovery has to happen across very few patients. A drug used by 100 million people can spread its development costs thinly. A drug for a rare disease with a few hundred eligible patients in the entire country has to recover the same kind of R&D bill from a much smaller base. Sumitomo Pharma projects just 133 Amshepri patients at peak; SanBio projects 39 patients per year for Akugo.

These drugs are one-time treatments. Unlike a chronic medication taken daily for life, Amshepri, Akugo, and Zolgensma are designed to be given once. The total lifetime cost to the system per patient may actually be lower than for some long-term drugs—but the upfront sticker shock is large.

According to Nikkei, Amshepri's price was calculated by adding only half of the standard operating profit margin to the manufacturing cost—because it received conditional and time-limited approval, not full approval. If and when full approval is granted, the price may be revised further upward.

How Japan's insurance system protects patients

A sticker price of ¥167 million sounds catastrophic, but very few Japanese patients will ever see a bill anywhere near that figure. Japan's universal health insurance system uses several layered protections.

Cost-sharing. Under public insurance, patients pay 30% of medical costs at the window (10–20% for the elderly and young children, depending on age and income). For a ¥167 million drug at 30% cost-sharing, that's still ¥50 million—an impossible sum for most families. That's where the next mechanism kicks in.

The High-Cost Medical Expense Benefit (高額療養費制度, kōgaku ryōyōhi seido). This caps the patient's out-of-pocket payment each month based on age and income. According to the Ministry of Health, Labour and Welfare (MHLW), under the current rules, a person under 70 with an annual income of around ¥3.7–7.7 million ($24,000–$49,000) pays at most around ¥87,000 (about $550) per month, even if their total medical bills run to millions of yen. The rest is reimbursed by their insurance.

The Designated Intractable Disease subsidy (指定難病医療費助成制度). SMA is on Japan's list of officially designated intractable diseases, which means SMA patients get additional subsidies beyond the standard high-cost benefit. Parkinson's disease is also a designated intractable disease at the moderate-to-severe stage. Traumatic brain injury is not currently on the list, although other support programs (e.g., disability benefits) may apply.

Local pediatric medical subsidies. Most municipalities provide free or nearly free medical care for children, which can further reduce out-of-pocket costs for younger patients.

Stacking these mechanisms, the actual amount a typical family pays out of pocket for these ultra-expensive drugs is usually in the range of tens of thousands of yen per month—not tens of millions—although exact figures depend on age, income, disease category, and municipality.

It's worth noting that Japan is currently in the middle of a phased revision of the High-Cost Medical Expense Benefit. According to MHLW, monthly caps will rise in stages starting August 2026, with income brackets further subdivided in August 2027. A new annual cap is being introduced to ease the burden on long-term patients. An earlier, larger increase proposed for 2025 was shelved after pushback from patient advocacy groups, including cancer patient organizations.

Will the prices come down over time?

Japan has built-in mechanisms that can lower drug prices, though none guarantee dramatic price drops for these specific products.

Biennial price revisions. All listed drugs are subject to price reviews every two years (with interim reviews now done in off-years for drugs with large gaps between official and market prices). Prices tend to fall over time as competition emerges and market prices drift below the official rate.

Market expansion repricing (市場拡大再算定). Under this rule, if a drug's annual sales exceed certain thresholds—¥15 billion ($95 million) and more than twice the originally projected sales, or ¥10 billion ($64 million) and more than ten times projected sales—the price can be reduced by up to 25%. The rule is designed to claw back excess profits if a drug ends up far more widely used than the manufacturer had predicted.

For these three drugs, projected peak sales are well below the thresholds that would trigger automatic market-expansion repricing (Amshepri ¥7.4 billion, Akugo ¥2.8 billion, Zolgensma Intrathecal ¥4.3 billion). So large automatic price cuts on this mechanism are unlikely unless patient numbers far exceed projections.

Full-approval repricing. Amshepri and Akugo currently hold conditional and time-limited approvals. Under this status, the price is set with only half the normal operating profit margin (per Nikkei). When a drug graduates to full approval after demonstrating efficacy in post-marketing studies, the manufacturer can apply for a price recalculation—which in this case might actually push the price up, not down.

Industry-wide pricing reforms. The Japanese government regularly debates the pricing of high-cost regenerative medicines. The FIRM industry group has argued the current framework doesn't adequately capture the value of one-time curative treatments, while patient and payer groups push for tighter cost controls. Future reforms could go in either direction.

The honest answer to "Will it get cheaper?" is: probably modestly over many years through biennial revisions, possibly not at all in the short term, and possibly more expensive after full approval. There is no equivalent of generic competition for cell and gene therapies in the near term.

A bigger picture: regenerative medicine becomes routine?

The May 20 listings represent something more than just three new approvals. They suggest that ultra-expensive cell and gene therapies are becoming a regular feature of Japan's drug pricing list, not a one-off curiosity.

The previous record-holder, the IV form of Zolgensma, was a remarkable exception when it was added to insurance in 2020. Last year saw Elevidys, a ¥304 million ($1.9 million) gene therapy for Duchenne muscular dystrophy, take that title. This week saw three more regenerative medicines added at once. According to MHLW, more such products are in the pipeline.

Japan's universal health insurance is one of the most generous in the world in covering treatments like these. The question for the years ahead is how to maintain that generosity as the cumulative price tag grows—particularly with Japan's rapidly aging population and shrinking workforce. The High-Cost Medical Expense Benefit reforms now being phased in are partly a response to this pressure.

How is it in your country?

Japan's approach is to add these drugs to universal insurance, set prices through a transparent (if contested) cost-calculation formula, then shield patients through a layered out-of-pocket cap. In the U.S., these therapies are typically negotiated with private insurers and Medicaid, often with outcomes-based contracts. In the U.K., NICE evaluates cost-effectiveness before NHS coverage. In Germany, the G-BA assesses added benefit and prices are negotiated centrally. Each system makes different trade-offs between access, sustainability, and patient burden.

If you or your family has dealt with the cost of a rare-disease therapy—or had to weigh whether to pursue a new treatment when the price tag ran into hundreds of thousands of dollars—we'd like to hear how the system worked, or didn't work, in your country.

Sources